<DOC>
	<DOCNO>NCT00805012</DOCNO>
	<brief_summary>To assess response rate docetaxel S-1 combination metastatic recurrent head neck squamous cell carcinoma</brief_summary>
	<brief_title>Docetaxel S-1 Head Neck Squamous Cell Carcinoma ( HNSCC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>histologically confirm HNSCC adequate primary site : oral cavity , oropharynx , hypopharynx , nasal cavity , paranasal sinus , head neck site ( except nasopharynx ) least one measurable lesion previous palliative chemotherapy ( adjuvant/neoadjuvant chemotherapy and/or radiotherapy longer 6 month ago permit ) 18 year old ECOG 0 1 adequate laboratory result write , informed consent pregnant lactate woman ( negative pregnancy test within 7 day require woman potential childbearing ) experimental drug clinical trial within 30 day malignancy ( exemption : treat basal cell carcinoma skin , CIS , cure cancer diseasefree interval 5 year ) patient organ transplantation grade 2 peripheral neuropathy grade 2 hearing loss severe , medical condition</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2011</verification_date>
	<keyword>S-1</keyword>
	<keyword>docetaxel</keyword>
	<keyword>head neck cancer</keyword>
	<keyword>Recurrent metastatic head neck squamous cell carcinoma</keyword>
</DOC>